Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injury
Jillian Strandberg, … , Lanlan Zhou, Wafik S. El-Deiry
Jillian Strandberg, … , Lanlan Zhou, Wafik S. El-Deiry
Published January 14, 2025
Citation Information: J Clin Invest. 2025;135(5):e173649. https://doi.org/10.1172/JCI173649.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 21

TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injury

  • Text
  • PDF
Abstract

Radiotherapy can be limited by pneumonitis, which is impacted by innate immunity, including pathways regulated by TRAIL death receptor DR5. We investigated whether DR5 agonists could rescue mice from toxic effects of radiation and found that 2 different agonists, parenteral PEGylated trimeric TRAIL (TLY012) and oral TRAIL-inducing compound (TIC10/ONC201), could reduce pneumonitis, alveolar wall thickness, and oxygen desaturation. Lung protection extended to late effects of radiation including less fibrosis at 22 weeks in TLY012-rescued survivors versus unrescued surviving irradiated mice. Wild-type orthotopic breast tumor–bearing mice receiving 20 Gy thoracic radiation were protected from pneumonitis with disappearance of tumors. At the molecular level, radioprotection appeared to be due to inhibition of CCL22, a macrophage-derived chemokine previously associated with radiation pneumonitis and pulmonary fibrosis. Treatment with anti-CCL22 reduced lung injury in vivo but less so than TLY012. Pneumonitis severity was worse in female versus male mice, and this was associated with increased expression of X-linked TLR7. Irradiated mice had reduced esophagitis characterized by reduced epithelial disruption and muscularis externa thickness following treatment with the ONC201 analog ONC212. The discovery that short-term treatment with TRAIL pathway agonists effectively rescues animals from pneumonitis, dermatitis, and esophagitis following high doses of thoracic radiation exposure has important translational implications.

Authors

Jillian Strandberg, Anna Louie, Seulki Lee, Marina Hahn, Praveen Srinivasan, Andrew George, Arielle De La Cruz, Leiqing Zhang, Liz Hernandez Borrero, Kelsey E. Huntington, Payton De La Cruz, Attila A. Seyhan, Paul P. Koffer, David E. Wazer, Thomas A. DiPetrillo, Stephanie L. Graff, Christopher G. Azzoli, Sharon I. Rounds, Andres J. Klein-Szanto, Fabio Tavora, Evgeny Yakirevich, Abbas E. Abbas, Lanlan Zhou, Wafik S. El-Deiry

×

Figure 2

Protection of mice from radiation pneumonitis and its dependence on genetic strain and TRAIL pathway agonist.

Options: View larger image (or click on image) Download as PowerPoint
Protection of mice from radiation pneumonitis and its dependence on gene...
(A and B) Representative H&E stains of lung tissue from male and female mice from C57BL/6, Dr5–/–, and Trail–/– backgrounds treated with ONC201, TLY012, or control gavage (n = 2 per sex per genotype per treatment) 13 days after irradiation (original magnification, ×40). (C) Quantification of percentage inflammation of Trail–/– female mice treated with TLY012 or control (n = 7 per treatment per group) showed significant decrease (P = 0.0385) in inflammation 2 weeks after thoracic irradiation of 20 Gy (1-tailed Mann-Whitney test). (D) Representative images of IHC staining of TLR7 in lung tissue from Trail–/– female and male mice at 2 weeks after irradiation (original magnification, ×10). Scale bars: 200 μm. (E) Quantification of positive staining of TLR7 in mouse lung separated by treatment group (n = 8 per treatment per group) (1-way ANOVA with Tukey’s post hoc test). (F) When separated by sex (n = 16 per sex), there was a statistically significant increase in female mice (P = 0.0045). Values are mean ± SEM (unpaired 2-tailed t test).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 21 X users
Referenced by 5 Bluesky users
1 readers on Mendeley
See more details